Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07537933 Tirofiban Hydrochloride Vascular occlusive disease Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07537933 clinical trial report covering Tirofiban Hydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07536373 Colchicine Chronic Limb-Threatening Ischemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07536373 clinical trial report covering Colchicine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2011260002 Ramantamig Refractory Multiple Myeloma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
JPRN-jRCT2011260002 clinical trial report covering Ramantamig, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07536763 Drospirenone/Estetrol Contraception Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07536763 clinical trial report covering Drospirenone/Estetrol, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07540221 Immune Globulin (Human)(Grifols) Polyradiculoneuropathy, Chronic Inflammatory Demyelinating Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07540221 clinical trial report covering Immune Globulin (Human)(Grifols), Phase 3, endpoints, sponsor, geography, readout timing and development white s
Latest Hotspot
8 min read
NCT07540442 Comekibart Dermatitis, Atopic Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07540442 clinical trial report covering Comekibart, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600122940 Omacetaxine Mepesuccinate Acute Myeloid Leukemia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600122940 clinical trial report covering Omacetaxine Mepesuccinate, Phase 3, endpoints, sponsor, geography, readout timing and development white spa
Latest Hotspot
8 min read
NCT07539623 Suzetrigine Complications of bariatric procedures Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07539623 clinical trial report covering Suzetrigine, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07540364 Samelisant Cataplexy Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07540364 clinical trial report covering Samelisant, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07540390 Anlotinib Dihydrochloride Nasopharyngeal Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07540390 clinical trial report covering Anlotinib Dihydrochloride, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600123076 RB-0026 Respiratory Syncytial Virus Infections Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
ChiCTR2600123076 clinical trial report covering RB-0026, Phase 3, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07542483 Lebrikizumab Nummular eczema Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
13 August 2026
NCT07542483 clinical trial report covering Lebrikizumab, Phase 3, endpoints, sponsor, geography, readout timing and development white space.